Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

01-04-2020 | Breast Cancer | Correction

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Authors: Thomas L. Gonzalez, Molly Hancock, Siqi Sun, Christina L. Gersch, Jose M. Larios, Wadie David, Jiantao Hu, Daniel F. Hayes, Shaomeng Wang, James M. Rae

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Excerpt

In the original publication of the article, the spelling of the sixth author’s given name was incorrect. The corrected author name should read as “Wadie David”. The original article has been corrected. …
Metadata
Title
Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
Authors
Thomas L. Gonzalez
Molly Hancock
Siqi Sun
Christina L. Gersch
Jose M. Larios
Wadie David
Jiantao Hu
Daniel F. Hayes
Shaomeng Wang
James M. Rae
Publication date
01-04-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05594-6

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Epidemiology

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases

Preclinical study

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

Epidemiology

The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

Clinical Trial

Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

Clinical trial

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer

Review

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits